ArticleMolecular imaging and biology2019
Artificial Neural Network-Based Prediction of Outcome in Parkinson's Disease Patients Using DaTscan SPECT Imaging Features.
Article in Molecular imaging and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Machine Learning Prediction of Hoehn and Yahr Scores at 5-Years Post-Movement disorders clinical practice · 2026Article
- Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Predicting Cognitive Decline in Parkinson's Disease Using Artificial Neural Networks: An Explainable AI Approach.Brain sciences · 2025Article
- Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinson's disease · 2025Review
- Baseline [NPJ Parkinson's disease · 2025Article
- Cross-modal fusion of brain imaging and clinical data for Parkinson's disease progression prediction.PloS one · 2025Article
- Quantitative evaluation ofScientific reports · 2024Article
- Radiomics incorporating deep features for predicting Parkinson's disease inEJNMMI physics · 2024Article
- Predicting the Response of Patients Treated withJournal of medical signals and sensors · 2024Article
- Radiomics insight into the neurodegenerative "Frontiers in nuclear medicine · 2023Review
- Machine learning within the Parkinson's progression markers initiative: Review of the current state of affairs.Frontiers in aging neuroscience · 2023Review
- Molecular Imaging in Parkinsonian Disorders-What's New and Hot?Brain sciences · 2022Review
- Diagnosis of Parkinson syndrome and Lewy-body disease usingAnnals of nuclear medicine · 2022Article
- Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning.European journal of nuclear medicine and molecular imaging · 2022Article
- A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinson's disease.EJNMMI research · 2021Article
- Applications of artificial intelligence in nuclear medicine image generation.Quantitative imaging in medicine and surgery · 2021Review
- Artificial intelligence in single photon emission computed tomography (SPECT) imaging: a narrative review.Annals of translational medicine · 2021Review
- Parkinson's Disease Diagnosis Using Neostriatum Radiomic Features Based on T2-Weighted Magnetic Resonance Imaging.Frontiers in neurology · 2020Article
- Advancements in Imaging Technologies and AI Integration for Neurodegenerative Disease Management: A Narrative Review.Molecular imagingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeQuantitative analysis of dopamine transporter (DAT) single-photon emission computed tomography (SPECT) images can enhance diagnostic confidence and improve their potential as a biomarker to monitor the progression of Parkinson's disease (PD). In the present work, we aim to predict motor outcome from baseline DAT SPECT imaging radiomic features and clinical measures using machine learning techniques. PROCEDURES: We designed and trained artificial neural networks (ANNs) to analyze the data from 69 patients within the Parkinson's Progressive Marker Initiative (PPMI) database. The task was to predict the unified PD rating scale (UPDRS) part III motor score in year 4 from 92 imaging features extracted on 12 different regions as well as 6 non-imaging measures at baseline (year 0). We first performed univariate screening (including the adjustment for false discovery) to select 4 regions each having 10 features with significant performance in classifying year 4 motor outcome into two classes of patients (divided by the UPDRS III threshold of 30). The leave-one-out strategy was then applied to train and test the ANNs for individual and combinations of features. The prediction statistics were calculated from 100 rounds of experiments, and the accuracy in appropriate prediction (classification of year 4 outcome) was quantified.
resultsOut of the baseline non-imaging features, only the UPDRS III (at year 0) was predictive, while multiple imaging features depicted significance. The different selected features reached a predictive accuracy of 70 % if used individually. Combining the top imaging features from the selected regions significantly improved the prediction accuracy to 75 % (p < 0.01). The combination of imaging features with the year 0 UPDRS III score also improved the prediction accuracy to 75 %.
conclusionThis study demonstrated the added predictive value of radiomic features extracted from DAT SPECT images in serving as a biomarker for PD progression tracking.
Indexed as
Identifiers
30847821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.